Antheia is revolutionizing drug discovery and manufacturing with its synthetic biology platform, using whole cell engineering to create complex molecules in yeast for next-generation plant-inspired medicines. Antheia aims to improve global access to essential medicines and address supply chain inequities. Founded by Dr. Christina Smolke and Dr. Kristy Hawkins from Stanford University, the company focuses on producing complex pharmaceutical ingredients sustainably and equitably.